MicroRNA‑383‑5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A

Zhao,Shasha; Gao,Xinyuan; Zang,Shuzhi; Li,Yunxia; Feng,Xianjun; Yuan,Xiaomei

doi:10.3892/ol.2017.6603

MicroRNA‑383‑5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A

Authors:
- Shasha Zhao
- Xinyuan Gao
- Shuzhi Zang
- Yunxia Li
- Xianjun Feng
- Xiaomei Yuan
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Hospital Affiliated to The Xinxiang Medical College, Xinxiang, Henan 453100, P.R. China
Published online on: July 18, 2017 https://doi.org/10.3892/ol.2017.6603
Pages: 3573-3579
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑associated mortality worldwide. MicroRNAs (miRNAs/miRs) serve a role in the occurrence and development of lung cancer. The aim of the present study was to analyze the expression and function of the proliferation‑associated miR‑383‑5p in lung adenocarcinoma (LAC). Samples of human LAC and matched adjacent normal lung tissues were surgically removed, and miR‑383‑5p expression and the pathological characteristics of lung adenocarcinoma were investigated. The present study revealed that miR‑383‑5p expression level was significantly decreased in LAC tissues and its expression levels were markedly associated with tumor size and differentiation. Overexpression of miR‑383‑5p in A549 and H1299 LAC cell lines inhibited cell proliferation by G1 cell cycle phase arrest and induction of apoptosis. Cancerous inhibitor of protein phosphatase 2A (CIP2A), a potential target gene of miR‑383‑5p, was inversely associated with miR‑383‑5p expression level in LAC tissues and cell lines. Furthermore, the results of the present study demonstrated that CIP2A was directly regulated by miR‑383‑5p and the restoration of CIP2A expression reversed the inhibitory effects of miR‑383‑5p on LAC cell proliferation. In conclusion, the results of the present study demonstrated that miR‑383‑5p was downregulated in LAC tissues. By targeting CIP2A, miR‑383‑5p exerts its anti‑proliferative function in LAC, suggesting its use a potential novel potential prognostic biomarker and therapeutic target for LAC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	She J, Yang P, Hong Q and Bai C: Lung cancer in China: Challenges and interventions. Chest. 143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
3	Wang H, Zhu LJ, Yang YC, Wang ZX and Wang R: MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 111:339–354. 2014. View Article : Google Scholar : PubMed/NCBI
4	Yan G, Yao R, Tang D, Qiu T, Shen Y, Jiao W, Ge N, Xuan Y and Wang Y: Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib. Med Oncol. 31:2032014. View Article : Google Scholar : PubMed/NCBI
5	Wang K, Liang Q, Wei L, Zhang W and Zhu P: MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor. Tumour Biol. 37:3823–3830. 2016. View Article : Google Scholar : PubMed/NCBI
6	Hu J, Qiu M, Jiang F, Zhang S, Yang X, Wang J, Xu L and Yin R: MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells. Tumour Biol. 35:8953–8961. 2014. View Article : Google Scholar : PubMed/NCBI
7	Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD and Camargo FD: Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 451:1125–1129. 2008. View Article : Google Scholar : PubMed/NCBI
8	Xing F, Wu K and Watabe K: MicroRNAs in cancer stem cells: New regulators of stemness. Curr Pharm Des. 20:5319–5327. 2014. View Article : Google Scholar : PubMed/NCBI
9	Qi J and Mu D: MicroRNAs and lung cancers: From pathogenesis to clinical implications. Front Med. 6:134–155. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gu Y, Wang XD, Lu JJ, Lei YY, Zou JY and Luo HH: Effect of mir-16 on proliferation and apoptosis in human A549 lung adenocarcinoma cells. Int J Clin Exp Med. 8:3227–3233. 2015.PubMed/NCBI
11	Arima C, Kajino T, Tamada Y, Imoto S, Shimada Y, Nakatochi M, Suzuki M, Isomura H, Yatabe Y, Yamaguchi T, et al: Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. Carcinogenesis. 35:2224–2231. 2014. View Article : Google Scholar : PubMed/NCBI
12	Chen DQ, Pan BZ, Huang JY, Zhang K, Cui SY, De W, Wang R and Chen LB: HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells. Oncotarget. 5:3333–3349. 2014. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Riffo-Campos ÁL, Riquelme I and Brebi-Mieville P: Tools for Sequence-Based miRNA Target Prediction: What to Choose? Int J Mol Sci. 17:pii: E1987. 2016. View Article : Google Scholar
15	Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, Chen H, Chen Q and Xiang W: Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 30:6812013. View Article : Google Scholar : PubMed/NCBI
16	Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong Y, Zhou Y, Zhang CY and Chen X: Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer. Oncotarget. 7:28075–28085. 2016. View Article : Google Scholar : PubMed/NCBI
17	Xiao P and Liu WL: MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. Int J Clin Exp Pathol. 8:10800–10807. 2015.PubMed/NCBI
18	Li YQ, Lu JH, Bao XM, Wang XF, Wu JH and Hong WQ: MiR-24 functions as a tumor suppressor in nasopharyngeal carcinoma through targeting FSCN1. J Exp Clin Cancer Res. 34:1302015. View Article : Google Scholar : PubMed/NCBI
19	Yu T, Liu L, Li J, Yan M, Lin H, Liu Y, Chu D, Tu H, Gu A and Yao M: MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget. 6:30239–30250. 2015. View Article : Google Scholar : PubMed/NCBI
20	Xu F, Zhang H, Su Y, Kong J, Yu H and Qian B: Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clin Transl Oncol. 16:980–985. 2014. View Article : Google Scholar : PubMed/NCBI
21	Chen L, Guan H, Gu C, Cao Y, Shao J and Wang F: miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL. Tumour Biol. 37:2497–2507. 2016. View Article : Google Scholar : PubMed/NCBI
22	Han S, Cao C, Tang T, Lu C, Xu J, Wang S, Xue L, Zhang X and Li M: ROBO3 promotes growth and metastasis of pancreatic carcinoma. Cancer Lett. 366:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
23	He Z, Cen D, Luo X, Li D, Li P, Liang L and Meng Z: Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol. 30:5572013. View Article : Google Scholar : PubMed/NCBI
24	Lian J, Tian H, Liu L, Zhang XS, Li WQ, Deng YM, Yao GD, Yin MM and Sun F: Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 1:e942010. View Article : Google Scholar : PubMed/NCBI
25	Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, Poon WS and Ng HK: MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 23:413–425. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lü M, Tian H, Cao YX, He X, Chen L, Song X, Ping P, Huang H and Sun F: Downregulation of miR-320a/383-sponge-like long non-coding RNA NLC1-C (narcolepsy candidate-region 1 genes) is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation. Cell Death Dis. 6:e19602015. View Article : Google Scholar : PubMed/NCBI
27	Xu Z, Zeng X, Tian D, Xu H, Cai Q, Wang J and Chen Q: MicroRNA-383 inhibits anchorage-independent growth and induces cell cycle arrest of glioma cells by targeting CCND1. Biochem Biophys Res Commun. 453:833–838. 2014. View Article : Google Scholar : PubMed/NCBI
28	Liu N, He QM, Chen JW, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, et al: Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 13:1112014. View Article : Google Scholar : PubMed/NCBI
29	Zheng Z, Qiao Z, Chen W, Gong R, Wang Y, Xu L, Ma Y, Zhang L, Lu Y, Jiang B, et al: CIP2A regulates proliferation and apoptosis of multiple myeloma cells. Mol Med Rep. 14:2705–2709. 2016.PubMed/NCBI
30	Liu Z, Ma L, Wen ZS, Cheng YX and Zhou GB: Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med Chem Lett. 5:113–118. 2013. View Article : Google Scholar : PubMed/NCBI
31	Liu J, Wang M, Zhang X, Wang Q, Qi M, Hu J, Zhou Z, Zhang C, Zhang W, Zhao W and Wang X: CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway. Tumour Biol. 37:2673–2682. 2016. View Article : Google Scholar : PubMed/NCBI
32	Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62. 2007. View Article : Google Scholar : PubMed/NCBI
33	Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ and Wang EH: CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol. 18:857–865. 2011. View Article : Google Scholar : PubMed/NCBI
34	Chao TT, Wang CY, Lai CC, Chen YL, Tsai YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ and Chen KF: TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. J Pharmacol Exp Ther. 351:352–358. 2014. View Article : Google Scholar : PubMed/NCBI
35	Lei N, Peng B and Zhang JY: CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer. Oncol Rep. 32:1689–1694. 2014.PubMed/NCBI